JP2023549765A5 - - Google Patents

Info

Publication number
JP2023549765A5
JP2023549765A5 JP2023528001A JP2023528001A JP2023549765A5 JP 2023549765 A5 JP2023549765 A5 JP 2023549765A5 JP 2023528001 A JP2023528001 A JP 2023528001A JP 2023528001 A JP2023528001 A JP 2023528001A JP 2023549765 A5 JP2023549765 A5 JP 2023549765A5
Authority
JP
Japan
Prior art keywords
cells
optionally
cell
lymphoma
tcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549765A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/058382 external-priority patent/WO2022099100A2/en
Publication of JP2023549765A publication Critical patent/JP2023549765A/ja
Publication of JP2023549765A5 publication Critical patent/JP2023549765A5/ja
Pending legal-status Critical Current

Links

JP2023528001A 2020-11-06 2021-11-08 Ｈａ－１抗原を認識する結合タンパク質及びその使用 Pending JP2023549765A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063110851P 2020-11-06 2020-11-06
US63/110,851 2020-11-06
US202063111462P 2020-11-09 2020-11-09
US63/111,462 2020-11-09
US202063129804P 2020-12-23 2020-12-23
US63/129,804 2020-12-23
US202163175350P 2021-04-15 2021-04-15
US63/175,350 2021-04-15
PCT/US2021/058382 WO2022099100A2 (en) 2020-11-06 2021-11-08 Binding proteins recognizing ha-1 antigen and uses thereof

Publications (2)

Publication Number Publication Date
JP2023549765A JP2023549765A (ja) 2023-11-29
JP2023549765A5 true JP2023549765A5 (enExample) 2024-11-18

Family

ID=81458633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528001A Pending JP2023549765A (ja) 2020-11-06 2021-11-08 Ｈａ－１抗原を認識する結合タンパク質及びその使用

Country Status (10)

Country Link
US (1) US20230398217A1 (enExample)
EP (1) EP4240490A4 (enExample)
JP (1) JP2023549765A (enExample)
KR (1) KR20230117576A (enExample)
AU (3) AU2021323388C1 (enExample)
CA (1) CA3197255A1 (enExample)
IL (1) IL302616A (enExample)
MX (1) MX2023005179A (enExample)
TW (1) TW202227499A (enExample)
WO (1) WO2022099100A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4633671A1 (en) * 2022-12-14 2025-10-22 Yale University Compositions and methods of use thereof for the treatment of virally driven cancers
WO2025217035A2 (en) * 2024-04-08 2025-10-16 Tscan Therapeutics, Inc. Use of anti-ha-1 and anti-ha-2 binding proteins for treatment of aml, all, and mds
TW202547854A (zh) * 2024-04-08 2025-12-16 美商帝斯肯醫療公司 Ｍａｇｅｃ２免疫原性肽、識別ｍａｇｅｃ２免疫原性肽之結合蛋白及其用途
WO2025231299A1 (en) * 2024-05-02 2025-11-06 Fred Hutchinson Cancer Center Tcr t cell therapy targeting ha-1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013003647A2 (pt) * 2010-07-28 2017-11-07 Immunocore Ltd receptores de células t.
CN109996868A (zh) * 2016-09-23 2019-07-09 弗雷德哈钦森癌症研究中心 特异性用于次要组织相容性(h)抗原ha-1的tcr及其用途
EP3833681A1 (en) * 2018-08-06 2021-06-16 Medigene Immunotherapies GmbH Ha-1 specific t cell receptors and their use
NL2021789B1 (en) * 2018-10-10 2020-05-14 Academisch Ziekenhuis Leiden Binding proteins specific for HA-1H and uses thereof

Similar Documents

Publication Publication Date Title
JP2023549765A5 (enExample)
US20230203124A1 (en) Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
JP2024517618A5 (enExample)
AU2022203507B2 (en) Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
US20240166758A1 (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
AU2021202223B2 (en) Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
JP7770188B2 (ja) 養子細胞療法のための標的共刺激を提供する受容体
MacDonald et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor
Biernacki et al. T-cell receptor–based immunotherapy for hematologic malignancies
JP2023534808A (ja) 養子細胞療法のための標的共刺激を提供する受容体
CA3144070A1 (en) T cell receptors recognizing r175h or y220c mutation in p53
JP2024546018A5 (enExample)
JP2024515646A5 (enExample)
EP3683229A1 (en) Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy
Nakatsugawa et al. CD4+ and CD8+ TCRβ repertoires possess different potentials to generate extraordinarily high-avidity T cells
WO2017055635A1 (en) Tcr and uses thereof
US20240360236A1 (en) Methods for targeted immunotherapy of acute myeloid leukemia (aml)
EP4223782A1 (en) Novel t cell receptors and immune therapy using the same for the treatment of cancer
Cereb et al. Induction of microvariant-specific CTL lines reactive to a single amino acid mismatch in bulk cultures using a transfectant expressing a single HLA class I molecule
TW202602496A (zh) 抗ｈａ－１及抗ｈａ－２結合蛋白用於治療ａｍｌ、ａｌｌ及ｍｄｓ之用途
JP2025516264A (ja) 多重化ｔ細胞受容体組成物、その併用療法、及び使用
Plewa Generation of TGFβR2 (-1) neoantigen-specific human T cell receptors from transgenic mice
Ortaldoª Identification of a proposed NK receptor
Jin et al. Activation of CD8+ T cells by allogeneic class II‐deficient B‐cell lines derived from patients with bare lymphocyte syndrome
Nguyen et al. The Immune System and Immunotherapy